Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026
Basics
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Market cap
126.1B USD
Enterprise value
154.9B USD
Full-time employees
32,500
Overall health
Strength:growing faster than most peersgrowing faster than peers
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:higher risk than most peers: less short-term liquidity (current ratio 1.53 vs a peer median of 2.59) and more debt relative to equity (1.97× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.53 vs peers 2.59) and more debt vs equity (1.97× vs peers 0.22×)
Ranks #319 of 1,157 healthcare companies (top 28%)
Operating margin at a 6-year high.21% in 2025, the best of the last 6 years.
Bristol-Myers Squibb kept 21% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Profit is backed by cash. Free cash flow is 123% of reported profit.
Bristol-Myers Squibb's free cash flow is 123% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.
Wide margins.Operating margin 24% (12 months to Jun 2026) vs a peer median of 7.1%.Operating margin 24% vs peers 7.1%.
Bristol-Myers Squibb keeps 24% of revenue as operating profit, more than 87% of peers (median 7.1%).
Steadier share price. Beta 0.18: tends to move less than the market.
Bristol-Myers Squibb's shares have swung less with the market than most peers' (beta 0.18, below the market's 1.0).
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Bristol-Myers Squibb
Is Bristol-Myers Squibb getting weaker?
Its latest SEC filing (Jul 30, 2026) got stronger: operating margin rose 3.3 points to 23.8%. Its overall score is unchanged at 62/100 since Oct 28, 2026.
How is Bristol-Myers Squibb valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 83/100 against 1,393 healthcare peers.Earnings yield 7.4% vs a peer median of 1.5% (stronger than 88% of peers).Earnings yield 7.4% vs peers 1.5% (stronger than 88% of peers).
Is Bristol-Myers Squibb growing?
Yes, faster than most of its peers. Growth scores 63/100 against 1,393 healthcare peers.Earnings per share growth 83.2% vs a peer median of 9.8% (stronger than 85% of peers).Earnings per share growth 83.2% vs peers 9.8% (stronger than 85% of peers).3-year revenue growth 2.9% vs a peer median of 5.8% (weaker than 63% of peers).3-year revenue growth 2.9% vs peers 5.8% (weaker than 63% of peers).
How profitable is Bristol-Myers Squibb?
More profitable than most of its peers. Profitability scores 88/100 against 1,393 healthcare peers.Return on assets 10.6% vs a peer median of 1.7% (stronger than 91% of peers).Return on assets 10.6% vs peers 1.7% (stronger than 91% of peers).
How risky is Bristol-Myers Squibb?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 0.18 vs a peer median of 0.63 (stronger than 93% of peers).Beta 0.18 vs peers 0.63 (stronger than 93% of peers).Debt / equity 1.97× vs a peer median of 0.22× (weaker than 89% of peers).Debt / equity 1.97× vs peers 0.22× (weaker than 89% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026
Got stronger
Operating margin rose 3.3 points to 23.8%
Previous quarter
Latest quarter
Change
Revenue (12 months)
48.5B USD
49.2B USD
+1.5%
Net income (12 months)
7.3B USD
9.3B USD
+27.6%
Operating margin
20.6%
23.8%
+3.3 pts
Free cash flow (12 months)
11.9B USD
11.4B USD
−3.9%
Debt
46.4B USD
43.9B USD
−5.5%
Cash
9.6B USD
8.7B USD
−8.9%
Shares outstanding
2.04B
2.04B
+0.0%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Drug Manufacturers - General companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
—
—
—
—
—
—
Operating margin
15.9%
18.0%
16.2%
-15.5%
20.8%
▲ 36 pts
Net margin
15.1%
13.7%
17.8%
-18.5%
14.6%
▲ 33 pts
Return on assets (ROA)
6.4%
6.5%
8.4%
-9.7%
7.8%
▲ 17 pts
Return on equity (ROE)
19.5%
20.4%
27.3%
-54.8%
38.2%
▲ 93 pts
Free cash flow margin
32.8%
25.9%
28.1%
28.9%
26.7%
▼ 2.2 pts
Current ratio
1.52×
1.25×
1.43×
1.25×
1.26×
▲ 0.2%
Quick ratio
1.43×
1.14×
1.31×
1.15×
1.14×
▼ 0.4%
Debt to equity
1.37×
1.39×
1.45×
3.15×
2.55×
▼ 19%
Interest coverage
5.53×
6.73×
6.25×
-3.84×
5.29×
▲ 238%
BMY price history
Price history is added with the daily price update and will appear after the next one.